Immunological checkpoint inhibitors enter adolescence

The Lancet Oncology

Volumn 14, Issue 11, 2013, Pages 1035-1037

  Nowak, Anna K ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; INDUCIBLE T CELL COSTIMULATOR; IPILIMUMAB; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; TICILIMUMAB;

CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DRUG RESPONSE; HUMAN; IMMUNE RESPONSE; LETTER; MALIGNANT MESOTHELIOMA; MELANOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MESOTHELIOMA; PLEURAL NEOPLASMS; SALVAGE THERAPY;

EID: 84884700351     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70401-7     Document Type: Letter

References (10)

1. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Nat Acad Sci USA 2003, 100:8372-8377.
2. Cameron F, Whiteside G, Perry C Ipilimumab: first global approval. Drugs 2011, 71:1093-1104.
3. Alegre ML, Frauwirth KA, Thompson CB T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001, 1:220-228.
4. Pardoll DM The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12:252-264.
5. Calabrò L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2013, published online Sept 11. http://dx.doi.org/10.1016/S1470-2045(13)70381-4.
6. Camacho LH, Antonia S, Sosman J, et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 2009, 27:1075-1081.
7. Kirkwood JM, Lorigan P, Hersey P, et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res 2010, 16:1042-1048.
8. Hersh EM, O'Day SJ, Powderly J, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs 2011, 29:489-498.
9. Weber JS, O'Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008, 26:5950-5956.
10. Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013, 31:616-622.